| Advanced Vision Therapies, Inc.: Company focused on the treatment of sight-threatening eye diseases such as age-related macular degeneration and finding a cure. |
| Amsterdam Molecular Therapeutics: Focused on developing gene therapies for lipoprotein lipase disorder, inflammatory bowel disease and neuroregeneration. Also provides contract development and manufacturing of gene and cell-based products in their GMP facility. |
| AraGene Inc.: Biotechnology company focused on the development of low-density lipoproteins as gene delivery systems. |
| Ark Therapeutics: A gene medicine company developing a broad range of products based on vascular and endothelial molecular biology to treat vascular and circulatory diseases and cancer. |
| BioVex: Gene delivery technology allowing pharmaceutical and genomics companies to assess the therapeutic value of identified genes and also allows genes to be used as therapeutic products to treat diseases from cancer to nervous and immune system disorders |
| Cell Genesys: Focused on the development and commercialization of cancer vaccines and gene therapies to treat various cancers including leukemia, hemophilia A and B, restenosis after angioplasty and Parkinson's disease. |
| Ceregene, Inc.: Pioneering genetic therapies for neurologic disorders. |
| Cobra Biomanufacturing: Contract manufacturing organisation focusing on the production of Protein, Viral and DNA-based therapeutics at cGMP grade. |
| Collateral Therapeutics: A product-driven cardiovascular gene therapy company, focused on the discovery, development and commercialization of novel and innovative non-surgical gene therapy products. |
| Copernicus Therapeutics, Inc.: Developing human gene therapy products for cystic fibrosis and hemophilia B and DNA vaccinations. The company creates proprietary PLASmin Complexes which are efficient non-viral vectors and REPLIsome vectors which allow replication of non-viral vectors. |
| Corautus Genetics: Biotech company developing new therapies for the treatment of patients with severe cardiovascular and peripheral vascular disease using gene transfer approaches. |
| Gene Therapy Systems: Commercial firm providing reagents for gene delivery and gene therapy research, including unique pGeneGrip fluorescently labeled plasmid vectors and GenePORTER cationic lipid transfection reagent. |
| Gentier Biosystems: Bioventure company established at Nihon University School of Medicine. Focuses on the use of antisense nucleotides and ribozymes for the treatment of cardiovascular and renal diseases. |
| GenVec: An emerging biopharmaceutical company developing novel gene therapies for diseases where local delivery of a therapeutic gene has potential benefits over currently available treatments. New product development initiatives have been formalized for coronary artery disease with BioBypass angiogen, restenosis prevention and cancer. |
| Henogen: A GMP biomanufacturing company located in Belgium, able to produce, purify and aseptically fill clinical batches of therapeutic proteins, monoclonal antibodies, plasmid DNA, vaccinal viruses or viral vectors for gene therapy. |
| Introgen Therapeutics, Inc.: A leader in the development of gene therapy products to treat a variety of cancers. |
| Molecular Medicine Bioservices, Inc.: A development and manufacturing company based in San Diego dedicated to the production of high-quality, clinical grade, gene and cell based therapeutics and reagents. |
| Nature Technology Corporation: Genetic technology and services company, focusing on plasmid DNA manufacturing, DNA vaccines and genetic vectors. |
| Oxford Biomedica: Focuses on developing gene transfer technologies for human gene therapy, gene-based immunotherapy, and gene-based drug discovery for cancer, AIDS, neurodegenerative and cardiovascular disease. |
| Puresyn, Inc.: Develops separation and purification processes for manufacturing gene delivery products such as supercoiled plasmids, synthetic oligonucleotides, recombinant adenovirus and adeno-associated virus. |
| Transgene S.A.: Gene therapy company based in France is developing products for cancer and cystic fibrosis. Vector platforms include adenovirus, retrovirus, vaccinia virus, cellular and synthetic vectors. |
| Valentis, Inc.: Developing gene-based therapeutics or "gene medicines" for the treatment of certain cancers, neuromuscular, cardiovascular, rheumatological and pulmonary diseases. |
| Vectorite Biomedica Inc.: Company focusing on the development of therapeutic lentivirus vector technology for the delivery of short interfering RNA molecules. |
| VirRx, Inc.: A biotechnology company with a primary interest in cancer gene therapy. |
Classical
